Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries

Overview of attention for article published in BMC Medicine, April 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (72nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 11 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 64 Dimensions

Readers on

mendeley: 145 Mendeley

Summary X Facebook Dimensions citations

So far, Dimensions has found 64 publications that cite this research output.

64

The most recent citing publications are shown below. View all 64 publications that cite this research output on Dimensions.

Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021

Article in The Lancet Infectious Diseases (April 2024)

Immunogenicity Evaluation of Respiratory Syncytial Virus Prefusogenic-F Based Virus-like-Particles Consisting of G and M Proteins in Mice

Preprint in Preprints.org (April 2024)

Exploratory analysis of the economically justifiable price of nirsevimab for healthy late‐preterm and term infants in Colombia

Article in Pediatric Pulmonology (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.